Analysts expect Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Rating) to post ($0.15) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Kintara Therapeutics’ earnings. Kintara Therapeutics reported earnings of ($0.23) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 34.8%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Kintara Therapeutics will report full-year earnings of ($0.59) per share for the current year. For the next financial year, analysts expect that the company will report earnings of ($0.55) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Kintara Therapeutics.
Kintara Therapeutics (NASDAQ:KTRA – Get Rating) last issued its quarterly earnings results on Friday, February 11th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.06.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Kintara Therapeutics by 77.3% during the 4th quarter. Geode Capital Management LLC now owns 517,966 shares of the company’s stock valued at $264,000 after purchasing an additional 225,902 shares during the period. Citadel Advisors LLC bought a new position in shares of Kintara Therapeutics during the fourth quarter valued at approximately $127,000. Renaissance Technologies LLC purchased a new stake in Kintara Therapeutics in the fourth quarter worth $104,000. Virtu Financial LLC boosted its holdings in Kintara Therapeutics by 371.4% in the fourth quarter. Virtu Financial LLC now owns 64,913 shares of the company’s stock valued at $33,000 after acquiring an additional 51,144 shares in the last quarter. Finally, Two Sigma Investments LP bought a new stake in Kintara Therapeutics in the third quarter valued at $47,000. 13.47% of the stock is currently owned by institutional investors.
Shares of Kintara Therapeutics stock traded down $0.01 during trading on Wednesday, reaching $0.28. The company’s stock had a trading volume of 14,515 shares, compared to its average volume of 987,740. Kintara Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.85. The firm’s 50-day moving average is $0.38 and its two-hundred day moving average is $0.57. The company has a market cap of $13.84 million, a price-to-earnings ratio of -0.40 and a beta of 1.64.
About Kintara Therapeutics (Get Rating)
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
- Get a free copy of the StockNews.com research report on Kintara Therapeutics (KTRA)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.